Genovis launches GingisREX™ and expands product portfolio

Genovis is launching GingisREX, a new enzyme aimed at customers throughout the proteomics market. The products that Genovis has launched to date have been used solely for modification of antibodies, while GingisREX can be used for proteins in general.

Genovis’ products are marketed under the name SmartEnzymes™ and are used in the biotech and pharmaceutical industries for characterization of biologics. What sets GingisREX apart from the other enzymes in the product portfolio is that the enzyme not only cleaves antibodies, it also cleaves other proteins specifically after the amino acid arginine. GingisREX is extremely reliable and more precise than similar enzymes on the market. It can be used alone or in combination with Genovis’ other enzymes to improve analysis results.

“With the launch of GingisREX we are now focusing on the entire proteomics market. Our customers currently use our enzymes for mass spec analysis and with GingisREX we have now expanded the range for this customer group, at the same time that we open up the available market. The product portfolio to date has only included enzymes for analysis of antibodies, but it is now expanding to include other proteins, and moving forward we intend to deliver several new enzymes for the entire proteomics market. This is both challenging and exciting,” says Fredrik Olsson, CEO of Genovis

For more information about GingisREX www.genovis.com/gingisrex

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com


ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs. 

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). 

Genovis shares are listed on Nasdaq First North Stockholm, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.


About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links